Specialized Hospital For Active Cardiology Treatement Cardiolife OOD — Clinical Trial Site

9 Registered trials

4 Currently recruiting

Organisation

Specialized Hospital For Active Cardiology Treatement Cardiolife OOD

Location

Varna, Bulgaria

Identifier

ORG-100044325

Address

Bulevard Republika 15, 9009, Bulgaria

Departments

Cardiology
Cardiology department
Department of Cardiology

Clinical trials at this site (9)

Search interface

HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
Clinical Randomised Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation. Recruiting

2025-521377-14-00 Atrial fibrillation 4 2025-10-06
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Recruiting

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
GenePHIT: A study to learn more about how well a new gene therapy (AB-1002) works and its safety in participants with congestive heart failu… Ended

2024-510581-17-00 Adult subjects with New York Heart Association (NYHA) C 4 2024-11-05
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype… Ended

2022-503022-13-00 Hypertriglyceridemia, Cardiovascular Diseases, Atherosc 5 2023-06-08
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17